What's Happening?
Harmony Biosciences Holdings, Inc. has announced a record quarterly revenue for the second quarter of 2026, with net product revenue for WAKIX® (pitolisant) reaching approximately $261 million. This marks a 30% increase year-over-year and a 21% growth
from the first quarter of 2026. The company attributes this success to strong demand for WAKIX and effective commercial execution. Harmony Biosciences has reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion. Additionally, the company announced a transition in its financial leadership, with Chief Financial Officer Glenn Reicin stepping down and Stephen Mollichella, Senior Vice President and Controller, stepping in as Interim Principal Financial Officer.
Why It's Important?
The record revenue highlights Harmony Biosciences' strong market position and the growing demand for its flagship product, WAKIX, which is used to treat rare neurological diseases. The reaffirmation of the annual revenue guidance suggests confidence in sustained business performance. The CFO transition is significant as it ensures continuity in financial leadership, which is crucial for maintaining investor confidence and operational stability. The company's ability to maintain its revenue targets despite leadership changes reflects its robust business strategy and market resilience.
What's Next?
Harmony Biosciences plans to release its full second quarter 2026 financial results and provide a business update on August 4, 2026. The company will continue its search for a permanent Chief Financial Officer while maintaining its focus on commercial execution and market expansion. Stakeholders will be watching closely to see how the interim financial leadership manages the transition and whether the company can sustain its growth trajectory.
